MW-101
Major Depressive Disorder (MDD)
Key Facts
About MindWalk Holdings
MindWalk Holdings is a clinical-stage biopharmaceutical company dedicated to addressing unmet needs in central nervous system (CNS) disorders. The company's strategy is built on a unique technology platform designed to modulate specific neural pathways with improved safety and efficacy profiles. Its lead programs are advancing in clinical trials for major depressive disorder and Alzheimer's disease. As a public entity, MindWalk aims to translate its scientific insights into transformative treatments for patients with debilitating neurological conditions.
View full company profileAbout MindWalk Holdings
MindWalk Holdings is a clinical-stage biopharmaceutical company dedicated to addressing unmet needs in central nervous system (CNS) disorders. The company's strategy is built on a unique technology platform designed to modulate specific neural pathways with improved safety and efficacy profiles. Its lead programs are advancing in clinical trials for major depressive disorder and Alzheimer's disease. As a public entity, MindWalk aims to translate its scientific insights into transformative treatments for patients with debilitating neurological conditions.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| XEN1101 | Xenon Pharmaceuticals | Phase 3 |
| BHV-5000 (NMDA antagonist) | Biohaven | Phase 1 |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| Navacaprant (NMRA-140) | Neumora Therapeutics | Phase 3 |
| NPH-101 | Neuphoria Therapeutics | Phase 2 |
| Itruvone (PH10) | Vistagen Therapeutics | Phase 2 |